Method of prevention of egg drop syndrome - 76 birds
(57) Abstract:The invention relates to veterinary medicine. The bird at the same time or within 24 hours after vaccination intramuscularly or intranasally administered soalan dose of 0.3-0.5 mg/kg body weight. Provides intense immunity and increase productivity. 5 table. The invention relates to veterinary medicine, in particular to methods of prevention of adenovirus infections in birds and can be used for the prevention of egg drop syndrome - 76 (EDS ' 76) chickens.Known methods of prevention of EDS ' 76 birds, including vaccines, mainly inactivated (1).Known methods provide long-term (10 months) immunity with relatively high protective level.The purpose of the invention is the enhancement of the prophylactic effectiveness of the method and the productivity of chickens.This goal is achieved by the fact that the bird on the background of vaccination additionally enter product "Tolan" (Deltain)."Tolan" (Deltain) is a natural, produced in the body regulatory nonapeptide with a stabilizing cellular homeostasis action, radical scavenging and membrane stabilizing action.
FIELD: medicine, cardiology.
SUBSTANCE: the suggested method should be performed at the background of medicinal therapy with preparations out of statins group, tevetene, polyoxidonium and conducting seances of plasmapheresis by removing 800 ml plasma twice weekly with N 5 due to additional intramuscular injection of immunophan 0.005%-1.0 with N 10 and fluimucyl 300 mg intravenously daily with N 5-10, total course of therapy lasts for 2 mo. The method provides modulation of leukocytic functional activity, moreover, due to altered cytokine profile and, thus, through disintegration of protein-lipid complexes participating in the development of atherosclerotic platelets.
EFFECT: higher efficiency of therapy.
FIELD: medicine, phthisiology, anesthesiology.
SUBSTANCE: during the day of operation one should perform autohemotransfusion, then introduce epocrine intravenously by drops at the dosage of 50-200 U/kg patient's body weight; next day after interference one should inject epocrine subcutaneously at the dosage of 25-100 U/kg; at hematocrit level being below 35% 48 h after operation it is necessary to repeat subcutaneous injection of the above-mentioned preparation at the dosage not exceeding 50 U/kg. The present innovation favors hemopoiesis stimulation in postoperational period, that, in its turn, accelerates postoperational rehabilitation in patients of this group and enables, also, to avoid allotransfusions being dangerous because of immunoconflicting reactions.
EFFECT: higher efficiency of compensation.
1 ex, 1 tbl
FIELD: pharmaceutical chemistry, medicine.
SUBSTANCE: in the suggested composition one should apply heptapeptide of Met-Glu-His-Phe-Pro-Gly-Pro sequence (heptapeptide A) for treating ischemic insult due to introducing 2 drops of compositions into each nasal canal 5-6 times daily for 10 d at disease of average severity degree, and in case of severe degree - per 3 drops of the present composition into each nasal canal 7 times daily for 10 d. The present innovation provides increased efficiency at decreased concentration of heptapeptide without any side effects.
EFFECT: higher efficiency of therapy.
2 cl, 6 dwg, 8 ex, 5 tbl
FIELD: genetic engineering, medicine.
SUBSTANCE: invention relates to T-cell receptor sequence being detected in patients with extended sclerosis and is useful in diagnosis and therapy. Oligonucleotide including sequence which represents or is derived from 5'-CTAGGGCGGGCGGGACTCACCTAC-3' or nucleotide sequence being fully complementary thereto. Oligonucleotide together with nuclear acid including nearly 15-30 oligonucleotides, which doesn't comprise oligonucleotide sequence and presents in region from Vβ to Jβ of Vβ13.1 gene in T-cell Vβ13.1-subgroup, wherein oligonucleotide and nuclear acid sequences don't present in the same chain of pair sequences of Vβ13.1 gene, is used in Vβ13.1 gene part amplification. In method for detection of LGRAGLTY motive, which is present in T-cell receptors of T-cell Vβ13.1-subgroup, oligonucleotide is used in combination with labeling particle. Once LGRAGLTY motive is detected, development monitoring and treatment are carried out by removing of LGRAGLTY motive-containing peptide.
EFFECT: simplified methods for detection of LGRAGLTY motive in T-cell receptors and treatment of patients with extended sclerosis.
21 cl, 7 dwg, 3 tbl, 3 ex
SUBSTANCE: peptide of the following formula: X-Pro-Gly-P, where X = Thr-Lys-Pro-Arg-; Lys-pro-Arg-; pro-Arg-; Arg-, being of untiulcerous activity. They should be applied at intraperitoneal injection at the dosage of 0.58-3.20 mcM g/kg for preventing and treating ulcers of gastro-intestinal tract.
EFFECT: higher efficiency and prophylaxis.
4 dwg, 5 ex